Medicare Issues Coverage Determination For Biocept's Target Selector Assay For Breast Cancer

Biocept Inc BIOC received a favorable final Local Coverage Determination expanding Medicare coverage for the use of its Target Selector assay to identify the HER2 biomarker from circulating tumor cells (CTCs). 

  • Reimbursement decision expands access to testing used to provide information to guide targeted treatment options for patients with breast cancer.
  • This coverage determination was effective July 4.
  • The Company also updates other initiatives, including CNSide, its proprietary test for neuro-oncology, and COVID-19 testing volume, which has reached over 450,000 samples.
  • Price Action: BIOC shares are up 1.63% at $4.07 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: GovernmentNewsPenny StocksHealth CareGeneralbreast cancerBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!